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Insights from experimental studies have been recently
translated into substantial advances in understanding the
pathogenesis of human membranous nephropathy (MN).
These include identification of neutral endopeptidase (NEP)
as the target antigen in alloimmune MN resulting from
fetomaternal immunization in NEP-deficient mothers, and
our demonstration that a high proportion of patients with
idiopathic MN (IMN) have circulating antibodies to the
M-type phospholipase A2 receptor (PLA2R), a trans-
membrane protein located on podocytes. Here we highlight
the studies that led to these discoveries and our current
knowledge about the possible role of anti-PLA2R
autoantibodies in the pathogenesis of IMN. Given that the
sensitivity and specificity of anti-PLA2R for IMN are475 and
100%, respectively, we foresee that a widely available assay
for anti-PLA2R will prove to be valuable for diagnosing IMN,
distinguishing it from secondary MN, and evaluating
response to therapy. We suggest reasons why 25% of
patients with IMN have tested negative for anti-PLA2R, and
propose possible explanations for the presence of
complement deposits in IMN despite the fact that
immunoglobulin G4 (IgG4), the predominant anti-PLA2R IgG
subclass, is incapable of activating the classical complement
pathway. Finally, we point out avenues to be explored,
including the events that induce production of anti-PLA2R,
their ability to cause podocyte injury, the role
of complement, and the nature of the antibodies in
secondary forms of MN.
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Membranous nephropathy (MN), despite its recognition as
one of the leading causes of idiopathic nephrotic syndrome,
remains a relatively rare disease. Why then, has it garnered so
much attention in the nephrology community over the last
several decades? The answer, in part, is that idiopathic MN is
a conceptually simple organ-specific autoimmune disease
with pronounced direct and secondary effects. Through
studies detailed below, it has become clear that circulating
autoantibodies bind to target antigens on the podocyte foot
process to initiate the disease process. There, the deposited
antibody–antigen complexes not only give rise to the
microscopic features by which the disease is characterized
but also activate the complement system, leading to injury to
the podocyte and subsequent proteinuria. This review will
serve to highlight the most recent additions to this ever-
evolving field of research.
WHAT DEFINES MN?
The features that characterize MN as a histopathological
entity result from the immune deposits that form at the base
of the foot processes of the glomerular visceral epithelial cell
or podocyte. The name membranous derives from the
thickened glomerular basement membrane (GBM) that is
often evident by light microscopy in later stages of the
disease. The immune deposits and, more important, the
additional matrix material laid down by the injured
podocytes are responsible for thickening of the GBM as the
disease progresses. Using a silver methenamine stain, David
Jones in 1957 first described argyrophilic ‘spikes’ or ‘clubs’
that represent this new matrix material between and around
the unstained immune deposits.1 In contrast, immunofluor-
escence for total immunoglobulin G (IgG) or IgG4 highlights
the deposits themselves, yielding fine granular staining in a
capillary loop pattern. Electron microscopy details the
amorphous, electron-dense deposits that occur in a sub-
epithelial and intramembranous position, as well as the
effacement of the podocyte foot processes and other signs of
podocyte injury.
SECONDARY FORMS OF MN
Most cases of MN in developed countries such as the United
States are idiopathic MN (IMN); however, a number of
secondary processes can also cause MN that is clinically and
histologically similar to IMN. Worldwide, chronic infections
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such as hepatitis B, malaria, syphilis, and schistosomiasis are
the most important causes of secondary MN. Systemic lupus
erythematosus can give rise to a membranous form of
glomerular disease, classified as class V lupus nephritis. Other
autoimmune diseases such as rheumatoid arthritis, auto-
immune thyroid diseases, and Sjo¨gren’s syndrome can all be
associated with MN. Historically, certain medications used
for the treatment of rheumatoid arthritis such as gold salts,
penicillamine, and some NSAIDs were causally linked to MN.
Solid tumors are associated with secondary MN more often
than chance alone would predict,2 and on rare occasions
remissions and relapses of the glomerular disease have been
noted to occur with removal or relapse of the malignancy.
Finally, MN can occur de novo after renal transplantation or
allogeneic hematopoietic stem cell transplantation, perhaps
reflecting alloimmunization to a minor histocompatibility
antigen expressed in the glomerulus.3,4
Secondary forms of MN often exhibit histopathological
clues that distinguish them from IMN, although this is not
always the case. As opposed to the exclusively subepithelial
and intramembranous deposits seen in IMN, secondary
forms, especially membranous lupus nephritis, often have
mesangial and subendothelial deposits. Tubuloreticular inclu-
sions may also been seen within the glomerular endothelium
on electron microscopy in lupus-associated MN. The IgG
subclasses found within the glomerular deposits also differ. In
contrast to the predominant IgG4 found in IMN, IgG2 and
IgG3 are typically most abundant in secondary (lupus- and
malignancy-associated) forms of MN.5–7 Finally, the nature of
the electron dense material itself may herald a secondary
cause. A form of MN characterized by spherular structures
within the subepithelial deposits has been described that
appears to be distinct from its idiopathic cousin.8
WHAT HAVE WE LEARNED FROM HEYMANN NEPHRITIS?
An experimental rat model developed by Walter Heymann in
the late 1950s has provided much of our knowledge about the
pathophysiological mechanisms of human MN.9 Known as
Heymann nephritis (HN), the model is induced by the active or
passive immunization of rats with fraction 1A (Fx1A), a mixture
of antigens derived from rat proximal tubular brush border.
These rats develop a proteinuric glomerulopathy with histolo-
gical features virtually identical to the human disease. The
model and its findings have been well reviewed in detail
elsewhere;10 however, several key findings that have helped to
establish the pathogenetic paradigm in MN need special
emphasis. There was initial debate as to the source of the
subepithelial deposits, and the prevailing early view was that
they represented circulating immune complexes that deposited
in the glomerulus. Others speculated that freely circulating
antigens were initially ‘planted’ in the GBM, followed later by
antibody binding. Definitive experiments using in vitro and ex
vivo perfused rat kidneys in a single-pass system showed that the
antibodies bind in situ to a target antigen intrinsic to the
glomerular capillary wall.11–13 The primary antigen targeted in
HN was ultimately identified as the transmembrane protein
megalin, an endocytic receptor in the low-density lipoprotein
receptor family that is located within coated pits on rat podocyte
foot processes and proximal tubular brush borders.14–18
Another key finding in the HN model is that the
development of proteinuria in most strains of rats is critically
dependent on complement activation within the glomerular
immune deposits. Rats depleted of complement with cobra
venom factor do not develop proteinuria when injected with
anti-Fx1A,19,20 and deficiency or depletion of the terminal
complement components C6 and C8 precludes assembly of the
membrane attack complex C5b-9 and prevents podocyte injury
and proteinuria, despite formation of subepithelial immune
deposits.21–23 These and subsequent findings in HN established
that complement-fixing anti-megalin antibodies aggregate the
antigen and activate complement leading to C5b-9-induced
sublethal podocyte injury facilitated by accompanying anti-
bodies that abrogate the effect of local complement-regulatory
proteins.24 The injured podocytes undergo a number of
cytopathological changes, including the generation of reactive
oxygen species and eicosanoids, reorganization of the actin
cytoskeleton, and dissociation of slit diaphragm complexes.25
Although the active and passive HN models have been
invaluable in defining pathogenic mechanisms in MN, they
do have certain limitations, some of which have called into
question HN’s relevance to the human disease. First and most
important is the fact that megalin is not expressed on human
podocytes.26 Second, attempts by several investigators failed
to disclose a similar antigen in human MN. Third, the
pathogenic IgG antibodies in HN are clearly able to fix
complement, whereas IgG4, the predominant antibody in
human MN, is believed to be an anti-inflammatory Ig
incapable of activating the classical pathway of complement.27
Fourth, although complement factors C3 and C5b-9 are
found in the same fine granular pattern as IgG in MN
biopsies,28 and the C5b-9 complex has been found in the
urine of such patients,29,30 it is important to note that there
are several animal models in which antibodies directed at
podocyte antigens cause proteinuria in the absence of
complement,31–33 which suggests a direct cytopathic effect.
ANTENATAL ALLOIMMUNE MN
The first and best evidence that the paradigm of in situ
immune complex formation also applies to human MN was
established by Debiec et al.34 in a rare form of neonatal MN.
In a single case report, followed later by several more cases,35
they described an infant born with the nephrotic syndrome,
the cause of which was found to be MN on renal biopsy.
Investigation into the cause revealed that the mother was
genetically deficient in neutral endopeptidase (NEP), and was
immunized to this protein during a previous miscarried
pregnancy from an NEP-positive father. In her subsequent
term pregnancy, circulating anti-NEP antibodies crossed the
placenta as well as the fetal GBM, bound NEP on the fetal
podocytes, and instigated a similar disease process as that
described in the experimental model. Two important features
should be noted in these cases of alloimmune antenatal MN.
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First, the disease resolved in the infant once the maternal
anti-NEP antibody was cleared from its system. Second,
proteinuria occurred only in the children of mothers who
had both IgG1 and IgG4 anti-NEP.35 A mother who was
found to have only the IgG4 subclass of anti-NEP did not
give birth to an affected infant. As IgG4 is unable to activate
the classical complement system, this suggests the need for
complement fixing IgG1 or IgG3 to cause clinically evident
disease.
IDENTIFICATION OF PLA2R AS TARGET ANTIGEN
Our laboratory has been involved in the search for the human
MN antigen, and similar to others, we approached the
problem by using sera from individuals with MN to screen
human glomerular proteins by immunoblot analysis. We soon
realized that a number of these sera contained antibodies that
specifically recognized a high-molecular-weight glycoprotein
in normal human glomeruli. This protein was detected only
in the absence of reducing agents, suggesting the presence of
one or more epitopes in the molecule whose conformation
was dependent on disulfide bonds and providing a potential
explanation as to why other laboratories had not identified
this protein using similar techniques. Capitalizing on several
properties of this glycoprotein and with mass spectrometric
analysis, we ultimately identified the protein reactive with
these antibodies as the M-type phospholipase A2 receptor
(PLA2R).36 This protein, also expressed in lung and on
neutrophils,37,38 appears largely restricted in the kidney to the
podocyte, in which it is abundantly expressed.36 Autoanti-
bodies to PLA2R are largely IgG4, the least abundant IgG
subclass in general, but known to be the predominant subclass
in IMN immune deposits. In confirmation of this latter point,
IgG4 could be colocalized with the PLA2R antigen within the
immune deposits of IMN biopsy samples, and anti-PLA2R
IgG could be eluted from biopsy samples of patients with
IMN, but not lupus-associated MN or IgA nephropathy. All
anti-PLA2R autoantibodies tested to date share the same
property of detecting PLA2R only in its non-reduced state
(LH Beck and DJ Salant, unpublished data).
PLA2R is an intriguing molecule, with properties that may
ultimately prove important for its proposed role as target
antigen in MN. It is a member of the mannose receptor family
of proteins, which includes the mannose receptor, Endo180,
DEC205, and the avian IgY receptor.39,40 Three of these
members have been shown to undergo a conformational
change, forming an N-terminal hairpin bend in response to
changes in pH or in association with ligand binding.41–43
Furthermore, all undergo constitutive endocytic recycling at the
plasma membrane,44 which could provide a constant source of
PLA2R at the podocyte foot process. We do not yet know
whether the anti-PLA2R antibodies interfere with the normal
function of PLA2R in podocytes, and the biological role of the
protein in the kidney is unknown. PLA2R has recently been
reported to promote replicative senescence in human fibro-
blasts, in part, by causing reactive oxygen species production
and DNA damage.45 It has also been shown to activate cytosolic
PLA2 leading to membrane phospholipid hydrolysis and
eicosanoid production.46 Similar processes have been observed
as downstream processes in the HN model,25 and it will be of
interest to see if such effects occur in human disease, mediated
through PLA2R. A transcript encoding a form of human
PLA2R that lacks the transmembrane and intracellular domains
has been described,47 but we have not detected this putative
soluble form in normal or MN serum.
Current sensitivity and specificity analyses show that anti-
PLA2R autoantibodies are present in greater than 75% of
individuals with IMN, but never in those with secondary
causes of MN, other glomerular or autoimmune diseases or
normal controls. There may be several reasons that the
sensitivity is not 100%, including potential technical issues
with the immunoblot assay, additional antigens targeted in
the disease, or misclassification of patients with IMN (who
may have an unrecognized secondary cause). However, our
leading hypothesis as to why there remain 25% of IMN
patients who do not have anti-PLA2R antibodies is that there
was an absence of immunologic disease activity at the time
when their serum was sampled, despite proteinuria. We have
shown presence of anti-PLA2R in patients initially nephrotic
from IMN, an absence in many of those that undergo
complete remission, and a recurrence of the autoantibodies
in cases of relapse. However, for reasons explained below, the
waters become muddier in those patients with subnephrotic
proteinuria who have achieved a partial remission.
It is important to make this distinction between pro-
teinuria, as a clinical marker of disease, and the presence of
anti-PLA2R, a marker of immunologic activity in IMN. The
two are closely, but not perfectly, related due to the time it
takes to form and resorb the subepithelial deposits (see
Figure 1). Protocol biopsies of renal allografts demonstrate
that the earliest deposits that occur in recurrent MN can
be associated with minimal proteinuria.48 Conversely,
proteinuria can remain after there is no further evidence
of circulating autoantibodies. We have shown a linear
correlation between anti-PLA2R and amount of proteinuria
(LH Beck and DJ Salant, unpublished data), and note that
at the point where autoantibody level reaches zero, there is
on average still residual proteinuria, in the 2–3 g/day range.
In patients who achieve complete remission in response
to immunosuppressive therapy, anti-PLA2R levels become
undetectable months before the proteinuria resolves
completely. Although these findings could alternatively
be explained by the continued circulation of additi-
onal unidentified pathogenic antibodies, they are perhaps
more compatible with residual structural deficits in the
absence of immunologic activity. In the experimental HN
model, transplantation of an affected kidney to a naive host
results in a significant decrease in proteinuria, but not
its complete elimination.49 In addition, GBM remodeling
and sclerotic changes that occur in the glomerulus
and interstitium in the face of longstanding MN can
also cause persistent proteinuria unrelated to an ongoing
immunologic process.
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POTENTIAL MECHANISMS OF PATHOGENESIS
Given the strong association of anti-PLA2R with disease
activity, it appears likely that these autoantibodies have
inherent pathogenicity. Proof, however, must await suitable
transgenic animal models, as all small animals tested thus far
do not express PLA2R on their podocytes, at least not in a form
recognized by human autoantibodies. Further proof of
pathogenicity might be forthcoming from studies of recurrent
MN post-renal transplantation if it is found that persistence or
reappearance of anti-PLA2R predates clinical or histological
evidence of MN. Regarding potential mechanisms by which
anti-PLA2R might cause podocyte damage, both complement-
dependent and independent mechanisms are possible. As noted
above, there is substantial evidence that complement is
activated in the glomerular immune deposits in idiopathic
MN; whereas, IgG4, the major IgG subclass present in the
glomeruli as well as the predominant anti-PLA2R subclass, is
generally regarded as being incapable of activating complement
through the classical pathway. While it is possible that the
smaller amounts of IgG1 anti-PLA2R detected in our studies
may be responsible for activating the classical pathway—as
reported in anti-NEP-induced alloimmune MN–most reports
have failed to detect C1q deposits in idiopathic MN. This
suggests the possibility that the alternative (AP) or mannan-
binding lectin pathways may be involved. Of the two, the
mannan-binding lectin pathway seems a better candidate
because C4b, a product of mannan-binding lectin activation
(but not the AP), is commonly found in idiopathic MN,
whereas factor B of the AP is not.50 In addition, mannan-
binding lectin has been identified in the glomeruli in a high
proportion of cases of idiopathic MN.51
Despite the well-documented presence of complement
products in MN, it certainly is possible that the initial events
involved in the pathogenesis of idiopathic MN are completely
unrelated to complement activation. For instance, there are well-
characterized cases in which human autoantibodies possess
agonist activities. Examples include the thyroid-stimulating
antibody in Grave’s disease52 and activating antibodies to the
angiontensin II receptor that cause hypertension in pre-
eclampsia and renal allograft rejection.53,54 Anti-PLA2R anti-
bodies may potentially interfere with the normal function of
PLA2R, either as a false agonist or as an antagonist. An
immediate answer to this question may not be possible, as the
function of PLA2R in the podocyte is unknown at this point.
However, the recent identification of PLA2R as a regulator of
replicative senescence in human fibroblasts,45 combined with the
demonstration of markers of senescence in the podocytes in MN
biopsies, 55 provides a plausible reason to investigate potential
agonist activity of anti-PLA2R.
ARE THERE OTHER INTRINSIC GLOMERULAR ANTIGENS?
Might there be other podocyte antigens that could also incite
MN? Although additional endogenous antigens might explain
the fact that sera from 25% of patients with IMN do not react
with PLA2R, this is not supported by our observations to
date. We have found that sera from this patient population do
not identify any other protein bands by immunoblot using
extracts of normal human glomeruli. Other investigators have
shown the presence of antibodies to other, mainly intracellular
glomerular proteins.56 Ronco and Debiec57 have additionally
reported low-level anti-NEP antibodies in adult patients with
IMN. Future studies will be needed to see if they arise
contemporaneously with or subsequent to anti-PLA2R
antibodies, and if both are ultimately needed for pathogenesis.
We are largely unaware of the processes underlying the
deposition of immune complexes in secondary forms of MN.
Our immunoblot assay does not suggest the presence of a
major intrinsic glomerular antigen. Other investigators have
shown the presence of nucleosomes within the subepithelial
deposits in lupus-associated MN.58 Similarly, the hepatitis B e
antigen (HBVe Ag) and tumor-associated markers have been
demonstrated in these deposits.59,60 It is not known whether
their presence is pathogenic, or whether they are just
nonspecifically trapped there. It has been hypothesized that
cationic antigens (histones, HBVe Ag) readily cross the GBM
and become planted in a subepithelial location, after which
circulating antibodies bind to form immune complexes. Others
have suggested that low-affinity immune complexes are
trapped at the luminal surface of the GBM, dissociate, and
then reform on the abluminal side to form subepithelial
immune complexes. Clearly, secondary MN is a field awaiting
further investigation with the molecular and proteomic tools
now at hand (Table 1).
NEW ROADS AHEAD
Detection of circulating anti-PLA2R autoantibodies is likely
to have a future role in diagnosis and monitoring of disease
activity in IMN. The robust sensitivity and specificity of the
test may afford patients with the nephrotic syndrome, a
Clinical disease
Treatment
Immunologic disease
100%
0%
Time
ProteinuriaAnti-PLA2R
Partial
remission
Complete
remission
Figure 1 |Relationship between clinical disease (proteinuria)
and immunological activity (circulating anti-PLA2R) in
idiopathic membranous nephropathy.
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diagnosis of IMN without requiring an invasive kidney
biopsy. Furthermore, in those who do receive a biopsy that
reveals MN, an absence of anti-PLA2R may prompt a more
thorough search for secondary causes. This distinction may
also be made on the grounds of immunofluorescence of the
biopsy tissue. In the secondary MN cases that we have tested,
the PLA2R antigen did not colocalize with IgG in the
immune deposits, but was rather still present in the podocyte
cell body as in normal kidneys.
Assessing the presence of anti-PLA2R in patients with sub-
nephrotic proteinuria after treatment for MN may also
provide important information. Knowledge of whether this
residual proteinuria represents structural changes that are best
treated conservatively, or a smoldering immunological activity
that requires further or different immunosuppressive therapy,
would be helpful clinically. This information would also be
valuable in selecting patients for clinical trials to avoid
including subjects with immunologically inactive disease.
As yet we have no good explanation why MN is limited to
the glomeruli given that PLA2R is also expressed in other
organs. As it may simply have to do with access of the
antibodies to the antigen across more or less permeable
capillary beds, more subtle explanations related to molecular
conformation or epitope masking are equally plausible. Finally,
we have not even scratched the surface to uncover the initiating
events that lead to the production of anti-PLA2R autoanti-
bodies. The fact that all samples tested to date identify the same
or closely related conformation-dependent epitope on PLA2R
with little evidence of epitope spreading to the rest of the
molecule may provide a clue if molecular modeling is possible.
Molecular mimicry as demonstrated in antineutrophil cyto-
plasmic antibody-associated vasculitis61 is an attractive possi-
bility worthy of investigation once the anti-PLA2R epitope is
better defined.
CONCLUSIONS
Fifty years after the introduction of the HN model, we are
now poised to enter a new era in the investigation of human
MN. Defining the pathogenic mechanisms by which anti-
PLA2R autoantibodies act is certainly paramount to a better
understanding and treatment options for this disease. The
decades of work performed in the HN model will serve as a
guide, although we expect many novel and interesting
findings along the way. Despite our current ignorance about
the precise pathomechanisms of anti-PLA2R, we anticipate
that measurement of these autoantibodies will become a
serologic test to diagnose IMN, to distinguish ‘idiopathic’
MN from secondary forms, and to monitor and tailor
immunosuppressive therapy.
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